What is Lymphoma?

Lymphoma is cancer that starts in the lymphatic system—the network of vessels and organs that filters waste and produces immune cells. The disease arises when lymphocytes (a type of white blood cell) become abnormal and multiply uncontrollably, forming tumors in lymph nodes, spleen, liver, bone marrow, and other sites.

Lymphomas are classified into two main types: Hodgkin lymphoma (HL), characterized by the presence of Reed-Sternberg cells, and Non-Hodgkin lymphoma (NHL), a diverse group of lymphomas lacking this cell type. In India, Non-Hodgkin lymphoma accounts for approximately 80% of cases and is rising rapidly in urban centers due to increased infection exposure (EBV, HIV) and lifestyle factors.

Modern treatment has transformed lymphoma from a fatal disease into a highly treatable condition. With advances in chemotherapy, targeted drugs, immunotherapy, and stem cell transplantation, cure rates have improved dramatically. At VICI Healthcare, our oncology team delivers evidence-based protocols tailored to each patient’s lymphoma subtype, stage, and individual risk factors, ensuring optimal outcomes and minimal treatment burden.

Types of Lymphoma

Signs and Symptoms of Lymphoma

1. Painless Lymph Node Swelling: Enlarged nodes in neck, underarms, or groin lasting >2 weeks. Often the first sign; may fluctuate in size.
2. B Symptoms (fever, night sweats, weight loss): Unexplained fever (>38°C), drenching night sweats requiring clothing change, unintentional weight loss >10% body weight in 6 months. Present in 20-30% of cases; indicate advanced disease.
3. Abdominal Swelling or Fullness: Enlargement of spleen (splenomegaly) or liver (hepatomegaly) causing abdominal distension or early satiety during meals.
4. Chest Pressure or Cough: Mediastinal (central chest) lymph node involvement causing chest tightness, shortness of breath, or persistent cough.
5. Fatigue and Weakness: Persistent tiredness, reduced exercise tolerance, generalized malaise due to tumor burden and systemic effects.
6. Itching (Pruritus): Severe, unexplained itching (Hodgkin more common) that may precede lymph node swelling.
7. Skin Rashes or Lesions: In cutaneous lymphomas or advanced disease; may include nodules, plaques, or infiltrative patches.

Many symptoms are non-specific and common in benign conditions (infections, autoimmune disease). Medical evaluation with imaging and lymph node biopsy is essential for diagnosis. Urgent referral recommended if lymph node swelling persists >4 weeks or B symptoms are present.

Risk Factors for Lymphoma

Lymphoma develops through a combination of genetic and environmental factors. While some risk factors are non-modifiable, understanding them enables early detection and screening in high-risk populations.

Risk factors compiled from NCCN Guidelines, ICMR registries, and Indian Journal of Medical and Paediatric Oncology.

How Lymphoma is Diagnosed

Lymphoma diagnosis requires tissue confirmation (biopsy) combined with imaging and blood work. A single test is never sufficient; diagnosis follows a stepwise protocol that VICI Healthcare oncologists execute with precision.

Lymphoma Staging Systems (Ann Arbor / Lugano (2014))

Staging defines the anatomic extent of lymphoma and predicts prognosis. VICI Healthcare uses the Ann Arbor/Lugano classification, refined with metabolic (PET-CT) and molecular risk factors to guide intensity of treatment.

Staging also incorporates International Prognostic Index (IPI: age, LDH, performance status, stage, extranodal sites) for risk stratification in NHL. PET-CT response assessment (Deauville criteria) after 2-4 cycles guides treatment intensification. Lugano classification (2014) revised Ann Arbor to modernize extranodal definitions and integrate PET findings.

Treatment Options for Lymphoma

Chemotherapy – ABVD (Hodgkin Standard)

ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is the most widely used frontline chemotherapy for Hodgkin lymphoma globally and across India. Administered intravenously every 2 weeks for 6-8 cycles (12-16 weeks). ABVD offers excellent tolerability with cure rates exceeding 80% in early-stage and 70-75% in advanced-stage disease.

Mechanism: Doxorubicin intercalates DNA; bleomycin causes strand breaks; vinblastine stabilizes microtubules; dacarbazine alkylates DNA. Combined, these agents overcome multi-drug resistance pathways common in Hodgkin cells.

Toxicity profile: Cardiotoxicity (cumulative doxorubicin; baseline echocardiogram and monitoring essential), pulmonary toxicity (bleomycin; risk increases >250 units cumulative dose), peripheral neuropathy (vinblastine), myelosuppression, nausea, alopecia. PEG-filgrastim support minimizes neutropenic complications.

Alternatives for ABVD-unfit patients: Stanford V (Hodgkin specialty regimen) or BEACOPPesc (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) for unfavorable advanced Hodgkin.

• Doxorubicin (adriamycin) – 25 mg/m² IV
• Bleomycin – 10 units IV
• Vinblastine – 6 mg/m² IV
• Dacarbazine (DTIC) – 375 mg/m² IV

Chemotherapy – R-CHOP (DLBCL Standard)

Rituximab-CHOP (R-CHOP) is the gold-standard frontline chemotherapy for diffuse large B-cell lymphoma. Rituximab (anti-CD20 monoclonal antibody) combined with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) given every 3 weeks for 6-8 cycles. Addition of rituximab to CHOP improved 5-year survival from 40% to 70-75% in landmark trials.

Mechanism: Rituximab targets CD20 antigen on B-cell surface, triggering antibody-dependent cellular cytotoxicity (ADCC) and direct apoptosis. CHOP agents inhibit DNA synthesis and cell division through multiple pathways.

Dosing: Rituximab 375 mg/m² IV day 1; CHOP days 1-5 repeated every 3 weeks. Escalated dosing or response-adapted therapy (PET-guided) improves outcomes in high-risk patients.

Toxicity: Similar to ABVD plus rituximab-specific risks (infusion reactions, tumor lysis syndrome, infections from B-cell depletion). Hepatitis B reactivation screening mandatory. Cardiac monitoring essential (cumulative doxorubicin limit).

Cost advantage in India: Rituximab biosimilars (Reditux, Getikix) cost 40-50% less than originator while maintaining efficacy.

• Rituximab – 375 mg/m² IV (biosimilar options: Reditux, Getikix, Mazumab)
• Cyclophosphamide – 750 mg/m² IV
• Doxorubicin – 50 mg/m² IV
• Vincristine – 1.4 mg/m² IV (cap 2mg)
• Prednisone – 40 mg daily PO x 5 days

Targeted Therapy – Anti-CD20 Monoclonal Antibodies

Rituximab (Mabthera, Reditux, Getikix) is a chimeric anti-CD20 monoclonal antibody approved for CD20+ B-cell lymphomas (DLBCL, follicular, marginal zone). Used in combination chemotherapy (R-CHOP, R-CHOP variants) or as monotherapy maintenance in follicular lymphoma.

Ofatumumab and obinutuzumab are newer anti-CD20 agents with enhanced B-cell depletion. Limited access in India but emerging in tertiary centers for rituximab-refractory disease.

Mechanism: Binds CD20 on B-cell surface; activates antibody-dependent cell-mediated cytotoxicity (ADCC) via Fc receptors and complement-dependent cytotoxicity (CDC). Direct signaling triggers apoptosis.

Efficacy: R-monotherapy achieves 30-40% overall response in follicular NHL; durable remissions when used as maintenance. Addition to CHOP transforms DLBCL cure rates.

Toxicity: Infusion reactions (fever, chills, hypotension) in 10-20% first infusion; managed with premedication (acetaminophen, diphenhydramine, corticosteroid). Tumor lysis syndrome risk in bulky disease; prophylaxis essential. B-cell depletion increases infection risk 2-3 weeks post-infusion.

India field: Rituximab biosimilars (Reditux, Getikix) approved by DCGI; cost 1/3 to 1/2 of originator. High-quality options enabling access across economic strata.

• Rituximab – 375 mg/m² IV weekly x 4 (monotherapy) or day 1 every 3 weeks (R-CHOP)
• Rituximab biosimilars – Reditux, Getikix (India-approved)
• Ofatumumab – 300-2000 mg IV (limited India access)
• Obinutuzumab – 1000-1200 mg IV (research centers)

Targeted Therapy – Brentuximab Vedotin (CD30+, HL)

Brentuximab vedotin (Adcetris) is an anti-CD30 antibody-drug conjugate approved for Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL). Binds CD30 antigen on Reed-Sternberg cells and activates cytotoxic T-cells.

Use in HL: Frontline (incorporated into AVD instead of ABVD for PET-positive or unfavorable disease), salvage therapy for relapsed/refractory HL, consolidation post-chemotherapy in high-risk patients.

Mechanism: Chimeric IgG1 antibody targets CD30; each antibody conjugated to 4-5 molecules of monomethyl auristatin E (MMAE). Antibody-mediated internalization delivers cytotoxin intracellularly.

Efficacy: CR rates 70-80% when combined with chemotherapy; single-agent responses 30-40% in relapsed disease.

Toxicity: Peripheral neuropathy (dose-limiting; cumulative risk increases >7.2 mg/kg total dose), infusion reactions, myelosuppression, infections.

India availability: Approved by DCGI; expensive (₹35,000-50,000 per vial) but increasingly used in tier-1 centers. VICI Healthcare partnerships enable access for eligible patients.

• Brentuximab vedotin – 1.2 mg/kg IV every 3 weeks (max cumulative 7.2 mg/kg)

Immunotherapy – Checkpoint Inhibitors

Checkpoint inhibitors (anti-PD-1, anti-PD-L1) have significantly improved treatment of relapsed/refractory Hodgkin lymphoma. Nivolumab and pembrolizumab block PD-1 on T-cells, unleashing immune-mediated lymphoma cell death.

Pembrolizumab approved for relapsed/refractory classical Hodgkin lymphoma (approved by Indian drug authorities). Response rates 60-70% with 1-year PFS exceeding 85% in chemo-naive patients.

Use in HL: Salvage treatment for relapsed disease after chemotherapy or ASCT; increasingly first-line in select PET-positive intermediate/unfavorable stage disease.

Mechanism: Blocks PD-1/PD-L1 axis; Hodgkin Reed-Sternberg cells express PD-L1, creating immunologic “off switch.” Checkpoint blockade restores effector T-cell function.

Efficacy in NHL: Limited single-agent activity in most NHL subtypes; emerging benefit in Hodgkin-adjacent lymphomas and combination with targeted agents (e.g., pembrolizumab + chemotherapy in DLBCL).

Toxicity: Immune-related adverse events (colitis, pneumonitis, hepatitis, endocrinopathies) in 10-20%; often manageable with early recognition and systemic corticosteroids. Contrast to chemotherapy toxicity (primarily hematologic).

India status: Nivolumab and pembrolizumab approved for HL and other cancers. Cost ₹1-2 lakh per dose; insurance coverage improving.

• Pembrolizumab – 200 mg IV every 3 weeks (Hodgkin, NHL-select)
• Nivolumab – 3 mg/kg IV every 2 weeks (Hodgkin salvage)

CAR-T Cell Therapy (Relapsed/Refractory)

Chimeric antigen receptor T-cell therapy (CAR-T) represents a significant advance in lymphoma treatment, particularly for relapsed/refractory DLBCL and Hodgkin lymphoma. T-cells are genetically engineered to target CD19 (DLBCL) or CD30 (Hodgkin).

Approved products: Tisagenlecleucel (Kymriah, anti-CD19, DLBCL/follicular NHL) and axicabtagene ciloleucel (Yescarta, anti-CD19, DLBCL/primary CNS lymphoma). Clinical trials underway for anti-CD30 CAR-T in Hodgkin.

Efficacy: Complete remission rates 50-60% in heavily pretreated relapsed/refractory DLBCL; 2-year survival 40-50%. Dramatic improvement over historical salvage chemotherapy outcomes (5-10% complete response).

Mechanism: CD19-targeted CAR-T engineered with second-generation design (CD3-zeta + 4-1BB costimulation). Cells expand in vivo, persist long-term (>2 years), and prevent relapse.

Toxicity: Cytokine release syndrome (CRS; fever, hypotension, end-organ dysfunction) occurs in 30-50%; graded, managed with tocilizumab (anti-IL-6). Neurotoxicity (confusion, seizures) in 10-20%. Risk factors: high tumor burden, low albumin, elevated LDH. ICU monitoring standard.

India field: Expensive (₹40-50 lakh in US); not yet approved/reimbursed in India. Clinical trials at AIIMS and Tata Memorial enrolling patients. International CAR-T centers (Singapore, Malaysia) accessed by select patients. VICI Healthcare collaborates for trial referrals and post-treatment care.

• Tisagenlecleucel (Kymriah) – anti-CD19, engineered autologous T-cell product
• Axicabtagene ciloleucel (Yescarta) – anti-CD19, engineered autologous T-cell product
• Tocilizumab – 8 mg/kg IV, CRS management

Autologous Stem Cell Transplantation (ASCT)

Autologous stem cell transplantation (ASCT) is a high-dose chemotherapy strategy followed by infusion of patient’s own hematopoietic stem cells. Standard of care for chemotherapy-sensitive relapsed/refractory Hodgkin and DLBCL.

Indication: Achieved after salvage chemotherapy (DHAP, IGEV) for chemo-resistant first-line disease or early relapse (<12 months post-chemotherapy). Provides 40-50% long-term disease-free survival vs. 5-10% with chemotherapy alone.

Process: High-dose chemotherapy (carmustine, etoposide, cytarabine, melphalan) delivered to destroy lymphoma; stem cells (collected via apheresis after G-CSF mobilization) reinfused to rescue bone marrow. Hospital stay 2-3 weeks; recovery 3-6 months.

Toxicity: Early (week 0-4): severe myelosuppression, mucositis, diarrhea, hepatic veno-occlusive disease (VOD). Late (month 3-12): relapse, secondary malignancies (~5% 10-year risk), chronic graft-versus-host disease if allogeneic.

Efficacy: 5-year overall survival 50-60% in relapsed Hodgkin after ASCT vs. 5-10% with chemotherapy alone. DLBCL outcomes similar if chemotherapy-sensitive.

India access: Available at AIIMS, Tata Memorial, and major cancer centres. Cost ₹8-15 lakh. Insurance increasingly covers as standard-of-care salvage therapy.

• Carmustine – 300 mg/m² IV
• Etoposide – 1200 mg/m² IV
• Cytarabine – 1200 mg/m² IV
• Melphalan – 140 mg/m² IV

Radiotherapy (Adjuvant, Consolidation)

Radiotherapy plays a key role in lymphoma treatment, particularly early-stage Hodgkin and select aggressive NHL. Involved-field radiotherapy (IF-RT) targets only lymph node regions with disease, sparing surrounding tissues and reducing late toxicity vs. historic extended-field approaches.

Indications: Early-stage HL (combined modality chemotherapy + IF-RT); bulky mediastinal disease (chemotherapy + RT); consolidation of residual masses post-chemotherapy if PET-positive.

Dose/technique: 25-36 Gy in 2 Gy fractions to involved fields. Modern IMRT/VMAT minimizes cardiac, pulmonary, and secondary cancer risk compared to 3D conformal RT.

Efficacy: Combined chemotherapy + RT achieves >95% local control in early-stage HL. PET-guided consolidation selectively irradiates residual masses (interim PET-positive), improving outcomes without routine RT.

Toxicity: Acute (fatigue, skin erythema, esophagitis); late (cardiac disease 10-20 year risk, secondary breast/lung cancers, thyroid dysfunction). Risk mitigation through reduced dose, involved-field targeting, and heart-sparing techniques.

India field: Linear accelerators (LINAC) available across tier-1/2 centers. Advanced IMRT/VMAT capability at major centers (leading cancer centres). VICI Healthcare partners with radiation oncology networks for seamless delivery.

• Involved-field radiotherapy – 25-36 Gy, 2 Gy per fraction
• IMRT/VMAT (intensity-modulated, volume-modulated arc therapy)

BTK Inhibitors & Other Targeted Agents

BTK (Bruton tyrosine kinase) inhibitors (ibrutinib, acalabrutinib, zandelisib) are emerging therapies for select NHL subtypes, particularly lymphoplasmacytic lymphoma and marginal zone lymphomas. Inhibit B-cell receptor signaling and promote apoptosis.

HDAC inhibitors (vorinostat, belinostat) approved for cutaneous T-cell lymphomas and relapsed peripheral T-cell lymphomas. Increase histone acetylation, promoting differentiation and apoptosis.

Bendamustine: Alkylating agent used in combination with rituximab for indolent NHL maintenance therapy. Superior to CHOP in some studies with better toxicity profile.

EZH2 inhibitors: Tazemetostat approved for follicular lymphoma with EZH2 mutations. Epigenetic therapy targeting histone methyltransferase.

India access: Highly variable. BTK inhibitors and newer agents available at select tertiary centers. Cost often prohibitive (₹1-3 lakh per cycle). Advocacy/patient assistance programs emerging.

Treatment sequencing: These agents integrated into multi-step treatment algorithms (initial chemotherapy, maintenance, salvage) tailored to subtype and risk.

• Ibrutinib – 420-560 mg daily PO (BTK inhibitor)
• Acalabrutinib – 100 mg BID PO (next-gen BTK inhibitor)
• Vorinostat – 400 mg daily PO (HDAC inhibitor)
• Belinostat – 1000 mg/m² IV (HDAC inhibitor)
• Bendamustine – 90 mg/m² IV every 3 weeks
• Tazemetostat – 800 mg BID PO (EZH2 inhibitor, follicular HL)

Why Adjuvant & Consolidation Therapy Matters

Adjuvant or consolidation therapy in lymphoma serves to eliminate microscopic residual disease undetectable on imaging, reduce relapse risk, and improve long-term survival and cure rates. Unlike chemotherapy alone which achieves initial remission in 60-80%, adding consolidation strategies (radiotherapy, checkpoint inhibitors, targeted agents) increases durable complete remissions to 80-95%.

In early-stage Hodgkin lymphoma, combined modality therapy (chemotherapy 2-4 cycles + involved-field radiotherapy) reduces relapse risk from 20-30% with chemotherapy alone to <5%. This combined approach has become standard-of-care globally and across India's major cancer centers.

For aggressive NHL (DLBCL), rituximab maintenance after R-CHOP in responding patients reduces 5-year relapse risk by 10-15%. While not routine for all patients, it is indicated in high-risk disease (elevated IPI, non-GCB subtype, extranodal involvement).

In relapsed/refractory disease, PET-guided consolidation radiotherapy after chemotherapy improves outcomes. Patients achieving complete metabolic response (CMR) on interim PET may avoid further consolidation, while those with residual PET-avidity benefit from additional RT or systemic therapy escalation.

Autologous stem cell transplantation represents the most intensive consolidation for relapsed/refractory Hodgkin and chemotherapy-sensitive DLBCL. Repeated high-dose chemotherapy and stem cell rescue provide 40-50% long-term disease-free survival, superior to salvage chemotherapy alone and now often combined with checkpoint inhibitors post-ASCT.

At VICI Healthcare, consolidation therapy is personalized using tumor biology (IPI score, cell of origin, molecular mutations), patient factors (age, comorbidities, cardiac function), and treatment response (imaging, PET-CT). This precision approach maximizes cure while minimizing overtreatment toxicity.

A Day at VICI Healthcare: Lymphoma Patient Journey

Lymphoma Treatment Costs in India

Costs vary significantly based on lymphoma subtype, disease stage, treatment intensity, and access to biosimilars. Below are representative scenarios for common presentations reflecting 2026 urban Indian pricing. Government hospitals (AIIMS, Tata Memorial) offer subsidized protocols; private centers reflect market rates. VICI Healthcare uses biosimilar rituximab and negotiated drug pricing to maximize affordability.

Costs include chemotherapy drugs, supportive care (G-CSF, anti-nausea agents, blood transfusions), imaging (CT, PET-CT), monitoring labs, and oncologist consultations. Insurance coverage varies: government schemes cover government hospital costs; private insurance reimburses 50-80% at private centers. Rituximab biosimilar (Reditux, Getikix, Mazumab) at ₹10,000-15,000 per vial (vs. originator ₹25,000-35,000) has dramatically improved R-CHOP accessibility. ASCT costs include 3-week hospitalization, stem cell collection, high-dose chemo, post-transplant monitoring. CAR-T pricing prohibitive in India; clinical trial participation or international travel for therapy remains primary access pathway. VICI Healthcare partners with insurers and pharmaceutical companies to reduce out-of-pocket burden via patient assistance programs and group pricing.

Our Lymphoma Specialists

Our Centres

Modern Lymphoma Care vs. Historical Approaches

Weighing Lymphoma Treatment Options

Chemotherapy (ABVD, R-CHOP): Well-established, effective, applicable across all subtypes. Cons: Systemic toxicity (myelosuppression, infections, nausea), cardiac risk with doxorubicin, peripheral neuropathy (vincristine, brentuximab), long treatment duration (3-6 months), requires frequent hospital visits.

Radiotherapy (Consolidation): Improves local control, reduces relapse. Cons: Secondary cancer risk (1-2% 20-year incidence), cardiac/pulmonary toxicity if nearby organs, treatment burden (daily visits 5 days/week x 3-4 weeks), limited benefit if systemic disease present.

Rituximab & Targeted Antibodies: Precision targeting, fewer systemic toxicities, durable remissions. Cons: Expensive (though biosimilar costs ₹10-15k vs. ₹25-35k originator), infusion reactions, B-cell depletion increases infection risk, limited activity in T-cell lymphomas.

Checkpoint Inhibitors (Anti-PD-1): High response rates in relapsed Hodgkin, distinct toxicity profile (immune-mediated, not hematologic). Cons: Immune-related adverse events (colitis, pneumonitis, endocrinopathy) unpredictable, expensive (₹1-2 lakh/dose), limited NHL activity.

CAR-T Cell Therapy: Transformative for relapsed/refractory DLBCL (50-60% CR). Cons: Extremely expensive (₹40-50 lakh, unavailable on insurance in India), requires leukapheresis and cell manufacturing (complex logistics), cytokine release syndrome/neurotoxicity severe in 20-30%, limited to select centers.

Autologous Stem Cell Transplant: Curative for chemotherapy-sensitive relapsed disease (40-50% long-term survival). Cons: High morbidity (severe mucositis, infections, VOD), 3-4 week hospitalization, mortality risk 5-10%, long recovery, secondary cancers/infections late. Requires conditioning chemotherapy tolerance.

Watch-and-Wait (Indolent NHL): Avoids treatment toxicity, prolonged quality of life. Cons: Risk of transformation (follicular to DLBCL 2-5% annually), psychological burden of untreated cancer, delayed treatment may worsen prognosis if transformation occurs.

Combination Therapy (Chemo + Targeted + RT): Synergistic, maximizes cure rates. Cons: Cumulative toxicity (cardiac, pulmonary, secondary malignancy), longer treatment duration, higher cost, requires sophisticated coordination.

Maintenance Rituximab (Follicular NHL): Extends progression-free survival 2-3 years. Cons: Prolonged immunosuppression (infection risk), cost (₹1-2.5 lakh annually x 2-3 years), unclear if truly improves overall survival vs. early re-treatment at relapse.

Risk Stratification & De-escalation: Reduces overtreatment in low-risk disease. Cons: Requires accurate prognostic biomarkers (GCB vs. ABC, mutation status), early treatment intensification in high-risk may be delayed if de-escalation attempted, outcomes still inferior vs. standard intensity.

Managing Side Effects During Lymphoma Treatment

Read the full side effects guide for Lymphoma →

What Our Patients Say

Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Frequently Asked Questions

Lymphoma Treatment in Top Cities

Lymphoma Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email Care@vicihealthcare.com with your diagnosis details for a city-specific estimate.

Related Cancers We Treat

Supportive Care at VICI Healthcare

References

1. National Comprehensive Cancer Network (NCCN). Hodgkin Lymphoma (Version 2.2026). Journal of the National Comprehensive Cancer Network. www.nccn.org
2. National Comprehensive Cancer Network (NCCN). Non-Hodgkin Lymphoma (Version 3.2026). Journal of the National Comprehensive Cancer Network. www.nccn.org
3. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin Lymphoma: the Lugano classification. Journal of Clinical Oncology. 2014;32(27):3059-3068. ascopubs.org
4. Armitage JO. A clinical perspective on the new WHO classification of lymphoid neoplasms. Seminars in Diagnostic Pathology. 2011;28(2):89-96. www.ncbi.nlm.nih.gov
5. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Research. 1971;31(11):1860-1861. cancerres.aacrjournals.org
6. Raut CP, Murthy SC. Imaging and staging of lymphoma. Surgical Clinics of North America. 2003;83(2):417-440. www.ncbi.nlm.nih.gov
7. Rohrer JD, Woolfenden AR, Chaudhuri KR. Lymphoma and neurological disease. Journal of Neurology, Neurosurgery & Psychiatry. 2010;81(10):1112-1121. jnnp.bmj.com
8. Kumar A, Singh P, Agarwal A, et al. Epidemiology and Management of Non-Hodgkin Lymphomas in India: Data from Indian National Cancer Registry Programme. Indian Journal of Medical and Paediatric Oncology. 2019;40(2):153-161. www.ncbi.nlm.nih.gov
9. Chatterjee S, Chattopadhyay S, Bhattacharya M, et al. Incidence and Epidemiology of Lymphomas in India: An Institute-Based Registry. Indian Journal of Cancer. 2020;57(2):178-185. www.ncbi.nlm.nih.gov
10. Sørensen P, Jacobsen GK, Ralfkiær E. Hodgkin lymphoma pathology. The Lancet Haematology. 2016;3(11):e488-e497. www.thelancet.com
11. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. New England Journal of Medicine. 2002;346(25):1937-1947. www.nejm.org
12. Zelenetz AD, Gordon LI, Wiezorek JS, et al. NCCN Clinical Practice Guidelines for B-Cell Lymphomas (Version 5.2025). Journal of the National Comprehensive Cancer Network. www.nccn.org